Current and historical daily PE Ratio for Protalix BioTherapeutics Inc (
) from 2007 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Protalix BioTherapeutics stock (PLX) PE ratio as of Apr 27 2024 is 57.5.
More Details
Protalix BioTherapeutics Inc (PLX) PE Ratio (TTM) Chart
Protalix BioTherapeutics Inc (PLX) PE Ratio (TTM) Historical Data
View and export this data going back to 2007. Start your Free Trial
Total 1217
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Protalix BioTherapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-28 | 57.5 | 2024-02-23 | 72.5 |
| 2024-04-26 | 57.5 | 2024-02-22 | 71.5 |
| 2024-04-25 | 59.0 | 2024-02-21 | 71.0 |
| 2024-04-24 | 60.5 | 2024-02-20 | 72.0 |
| 2024-04-23 | 60.0 | 2024-02-16 | 73.5 |
| 2024-04-22 | 59.0 | 2024-02-15 | 76.0 |
| 2024-04-19 | 57.5 | 2024-02-14 | 74.0 |
| 2024-04-18 | 56.5 | 2024-02-13 | 71.0 |
| 2024-04-17 | 57.5 | 2024-02-12 | 74.5 |
| 2024-04-16 | 57.0 | 2024-02-09 | 73.5 |
| 2024-04-15 | 57.0 | 2024-02-08 | 75.0 |
| 2024-04-12 | 59.0 | 2024-02-07 | 74.0 |
| 2024-04-11 | 61.0 | 2024-02-06 | 76.5 |
| 2024-04-10 | 63.0 | 2024-02-05 | 72.0 |
| 2024-04-09 | 66.0 | 2024-02-02 | 72.5 |
| 2024-04-08 | 65.0 | 2024-02-01 | 73.5 |
| 2024-04-05 | 58.5 | 2024-01-31 | 72.5 |
| 2024-04-04 | 60.5 | 2024-01-30 | 74.5 |
| 2024-04-03 | 62.0 | 2024-01-29 | 77.0 |
| 2024-04-02 | 62.0 | 2024-01-26 | 74.0 |
| 2024-04-01 | 62.5 | 2024-01-25 | 75.5 |
| 2024-03-28 | 63.0 | 2024-01-24 | 73.5 |
| 2024-03-27 | 62.5 | 2024-01-23 | 77.5 |
| 2024-03-26 | 61.0 | 2024-01-22 | 78.5 |
| 2024-03-25 | 61.0 | 2024-01-19 | 75.5 |
| 2024-03-22 | 63.5 | 2024-01-18 | 73.5 |
| 2024-03-21 | 66.0 | 2024-01-17 | 77.0 |
| 2024-03-20 | 67.0 | 2024-01-16 | 77.5 |
| 2024-03-19 | 65.0 | 2024-01-12 | 80.5 |
| 2024-03-18 | 63.5 | 2024-01-11 | 82.0 |
| 2024-03-15 | 66.5 | 2024-01-10 | 85.5 |
| 2024-03-14 | 68.5 | 2024-01-09 | 87.0 |
| 2024-03-13 | 76.0 | 2024-01-08 | 89.5 |
| 2024-03-12 | 71.5 | 2024-01-05 | 87.0 |
| 2024-03-11 | 72.0 | 2024-01-04 | 87.0 |
| 2024-03-08 | 74.5 | 2024-01-03 | 89.5 |
| 2024-03-07 | 73.0 | 2024-01-02 | 91.0 |
| 2024-03-06 | 74.0 | 2023-12-29 | 89.0 |
| 2024-03-05 | 76.0 | 2023-12-28 | 90.0 |
| 2024-03-04 | 78.5 | 2023-12-27 | 36.2 |
| 2024-03-01 | 81.0 | 2023-12-26 | 36.8 |
| 2024-02-29 | 81.5 | 2023-12-22 | 36.0 |
| 2024-02-28 | 77.0 | 2023-12-21 | 34.8 |
| 2024-02-27 | 78.0 | 2023-12-20 | 34.2 |
| 2024-02-26 | 74.5 | 2023-12-19 | 35.0 |
Protalix BioTherapeutics Inc (PLX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Protalix BioTherapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US74365A1016
Description
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers